ACADIA posts results of Phase 3 carbetocin nasal spray trial in Prader-Willi syndrome
The study, completed in August 2025, enrolled 175 participants and evaluated carbetocin nasal spray versus placebo over 12 weeks. Results were first posted on ClinicalTrials.gov on October 15, 2026.
Primary source
ClinicalTrials.gov results record, October 15, 2026
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Read the source: Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation